Search filters

Filters
Clear All

Phase

  • 182
  • 151
  • 2
  • 188
  • 147
  • 17
  • 373
  • 1196
  • 568
  • 28
  • 44
  • 2
  • 1128
  • 1197
  • 5

Found 1202 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Visceral adipose tissue and frailty in idiopathic pulmonary fibrosis
18 years - 99 years
All genders
The research study is being conducted to better understand how fat and muscle are related to disability and health-related quality of life in people with idiopathic pulmonary fibrosis.
 Study comparing the effect of crizanlizumab plus standard of care to standard of care alone on renal function in sickle cell disease patients,with chronic kidney disease due to sickle cell nephropathy (STEADFAST).
16 years - 99 years
All genders
Phase 2
The main purpose of the study is to explore the effect of crizanlizumab on kidney function in people with long-term kidney disease caused by SCD. Kidney function of patients who receive crizanlizumab in addition to any regularly prescribed medications will be compared to that of patients who receive their regularly …
 Study Evaluating Participants who Received CanGaroo  Envelope  Tyrx Envelope  or No Envelope During CIED Implantation
18 years - 99 years
All genders
People who have had surgery to implant a medical device that helps their heart may have had their surgery done in slightly different ways. In this study, the investigators are looking for people to participate who need to undergo another surgical procedure to change or revise their implanted heart device. …
 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
18 years - 39 years
All genders
Phase 3
Interventional
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
 Disrupt CAD III With the Shockwave Coronary IVL System
18 years - 99 years
All genders
The study design is a prospective, multicenter, single-arm, global IDE study to evaluate the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic coronary arteries prior to stenting. Disrupt CAD III is being conducted as a staged pivotal study.
 TEGSEDI study
18 years - 99 years
All genders
Phase 4
This research study is being done at the request of the US Food & Drug Administration (FDA) to collect additional safety information for the commercially available drug TEGSEDI. This research study is being conducted to examine any changes in health or side effects occurring within 24 hours following treatment with …
 Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
18 years - 99 years
All genders
Phase 1
This is a Phase 1, multiple-dose, ascending dose-escalation and expansion study of XmAb22841, both as a monotherapy and in combination with pembrolizumab. The study is designed in 2 parts, Part A and Part B. Part A is a 3 + 3 dose escalation designed to assess both XmAb22841 administered as …
 Inhaled AR-501 in Adults with P. Aeruginosa Infected Cystic Fibrosis Subjects
18 years - 49 years
All genders
Phase 1
This is a study of AR-501 (gallium citrate) solution, administered via inhalation, in adults with P. aeruginosa infected cystic fibrosis (CF). The study will evaluate the safety and pharmacokinetic (PK) and efficacy of repeat administrations of inhaled AR-501 solution in P. aeruginosa infected CF.
 Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
18 years - 99 years
All genders
Phase 1
Interventional
ASTX295 is a synthetic small molecule that acts as an antagonist of Murine Double Minute 2 (MDM2; human homolog also known as HDM2). Study ASTX295-01 is a study with ASTX295 in subjects who are refractory or have relapsed after treatment with standard of care therapies, or for whom standard life-prolonging …
 Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
18 years - 99 years
All genders
Phase 2
Interventional
This study will assess the safety, tolerability, pharmacokinetics, and antiviral activity of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma viremia.
971 - 980 of 1202